What is the role of the HIV‑1 proviral DNA test in diagnosing and managing HIV infection?

Role of HIV-1 Proviral DNA Testing

HIV-1 proviral DNA testing serves as a critical biomarker for measuring viral reservoir size, predicting disease progression and treatment response, and diagnosing HIV infection when RNA testing is unavailable—particularly in infants born to HIV-positive mothers.

Primary Clinical Applications

1. Viral Reservoir Quantification and Cure Research

The most sophisticated application of proviral DNA testing is measuring the HIV reservoir, which is essential for evaluating cure-directed interventions. The Intact Proviral DNA Assay (IPDA) represents the current gold standard, eliminating 97% of defective proviruses and overestimating reservoir size by only ~1.5-fold 1. This is substantially more accurate than total HIV DNA measurements, which include predominantly defective proviruses that cannot produce replication-competent virus.

For clinical trials targeting HIV eradication:

• IPDA provides medium-cost, relatively fast quantification of cells encoding intact versus defective proviral DNA 1
• Does not require cell stimulation or expansion, making it more practical than viral outgrowth assays
• Caveat: Sequence polymorphisms may preclude measurement in some patients, and the assay is clade-dependent 1
• The newer HIV-1 B&C IPDA addresses this limitation, correctly identifying 100% of intact subtype B and 86% of subtype C sequences, compared to only 12% subtype C identification with the original IPDA 2

2. Prognostic Value in Treated and Untreated Patients

Total HIV DNA load independently predicts progression to AIDS and death, regardless of HIV RNA load and CD4 count 3. This makes it clinically valuable beyond just measuring viral replication:

• In untreated patients: Baseline total HIV DNA predicts response to antiretroviral therapy (ART) 3
• During ART: Total HIV DNA declines but remains quantifiable, reflecting infection history (HIV RNA zenith, CD4 nadir) and treatment efficacy (residual viremia, immune restoration) 3
• In acute infection: HAART significantly reduces both total HIV-1 DNA (from 997±676 to 262±174 copies/10⁵ PBMC) and 2-LTR HIV-1 DNA over 12 months, while untreated patients show no significant variation 4

3. Diagnosis in Specific Populations

Proviral DNA PCR is the recommended method for diagnosing HIV-1 infection in infants in resource-limited settings 5. This is critical because:

• Maternal antibodies persist in infants, making antibody testing unreliable until 18 months
• RNA testing may miss infection during the eclipse phase
• Point-of-care DNA extraction methods can detect as few as 20 copies of HIV-1 proviral DNA from 100 μL of blood with 99% sensitivity and 100% specificity 5
• Results can be obtained while mothers wait, rather than the typical several-week delay 5

4. Drug Resistance Assessment in Virologically Suppressed Patients

For individuals on suppressive ART requiring therapy switches, HIV DNA-based resistance testing has become increasingly necessary 6. This addresses a critical gap:

• When plasma HIV RNA is undetectable, RNA-based genotyping is impossible
• Archived resistance mutations in proviral DNA can predict treatment failure with new regimens
• Important caveat: HIV DNA resistance testing has distinct technical and biologic challenges compared to RNA testing, requiring specific quality-assessment procedures and clinical validation 6

Complementary Role to RNA Testing

HIV-1 DNA load indicates the spread of infection, while plasma RNA load indicates active replication 7. This distinction is crucial:

• DNA quantification provides information about reservoir status beyond viral replication 7
• Identifies viral reservoirs in resting memory CD4+ T cells, monocytes, and macrophages—major obstacles to cure 7
• Can detect both wild-type and drug-resistant viruses stored in reservoirs 7

CNS Reservoir Assessment

Recent evidence shows intact HIV DNA is frequently present in cerebrospinal fluid (CSF) regardless of ART status, with total CSF HIV DNA significantly higher than in matched PBMCs 8. This has implications for:

• Understanding HIV persistence in the CNS
• Evaluating CNS-targeted cure strategies
• Potential correlation with cognitive dysfunction, particularly executive function 8

Practical Limitations

While proviral DNA testing provides valuable information, clinicians should recognize:

• Most proviral DNA is defective: Total HIV DNA overestimates the replication-competent reservoir because 95-98% of proviruses are defective 1, 3
• Clade dependency: Standard assays may fail in non-B subtypes; use subtype-specific assays when appropriate 1, 2
• Does not measure inducibility: DNA presence doesn't confirm the virus can be reactivated 1
• Cost and complexity: IPDA and sequencing-based methods are more expensive and require specialized expertise compared to routine RNA testing 1

Clinical Decision Algorithm

Use HIV-1 proviral DNA testing when:

1. Diagnosing HIV in infants <18 months (first-line in resource-limited settings)
2. Assessing drug resistance in patients with undetectable viral loads considering treatment switch
3. Evaluating reservoir size in cure research or clinical trials
4. Predicting long-term outcomes when baseline measurements are available
5. Monitoring treatment efficacy in acute infection alongside standard markers

Choose IPDA over total HIV DNA when accurate reservoir quantification is needed, accepting higher cost for substantially improved specificity 1.